NEUP
What one share of Neuphoria Therapeutics holds
Pharmaceutical Preparations
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs.
Neuphoria Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.27 |
|---|---|
| Profit | −$3.06 |
| Cash and investments | $3.67 |
| Book value | $4.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$18.62 | — | −$17.64 | — | $15.84 |
| 2025 | $9.64 | −$0.23 | — | $0.05 | — | $9.60 |
| 2026 | $0.27 | −$3.06 | — | −$2.81 | — | $4.55 |